Article | Published:

Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacological agents for treating obsessive-compulsive disorder (OCD). However, because nearly half of patients show insufficient SSRI responses, serotonergic dysfunction in heterogeneous OCD patients should be investigated for precision medicine. We aimed to determine whether functional connectivity (FC) of the raphe nucleus (RN), the major source of most serotonergic neurons, was altered in OCD patients and could predict the SSRI response. A total of 102 medication-free OCD patients and 101 matched healthy control (HC) subjects participated in resting-state functional magnetic resonance imaging. Among them, 54 OCD patients were treated with SSRIs for 16 weeks, resulting in 26 responders and 28 nonresponders. Seed-based whole brain FC with the RN as a seed region was compared between the OCD and HC groups, as well as between SSRI responders and nonresponders. FC cluster values showing significant group differences were used to investigate factors correlated with symptomatic severity before treatment and predictive of SSRI response. Compared to HCs, OCD patients exhibited significantly larger FC between the RN and temporal cortices including the middle temporal gyrus (MTG), paracingulate gyrus, amygdala, hippocampus, putamen, thalamus, and brain stem. Greater RN-left MTG FC was positively correlated with OC symptom severity at baseline. In addition, larger FC of the RN-left MTG was also found in SSRI nonresponders compared to responders, which was a significant predictor of SSRI response after 16 weeks. The FC of RN may reflect the neurobiological underpinning of OCD and could aid future precision medicine as a differential brain-based biomarker.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Lochner C, Stein DJ. Heterogeneity of obsessive-compulsive disorder: a literature review. Harv Rev Psychiatry. 2003;11:113–32.

  2. 2.

    Stein DJ, Koen N, Fineberg N, Fontenelle LF, Matsunaga H, Osser D, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2012;14:211–9.

  3. 3.

    Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164:5–53.

  4. 4.

    Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychol Med. 2016;46:357–66.

  5. 5.

    Hasselbalch SG, Hansen ES, Jakobsen TB, Pinborg LH, Lonborg JH, Bolwig TG. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatr Scand. 2007;115:388–94.

  6. 6.

    Mundo E, Richter MA, Zai G, Sam F, McBride J, Macciardi F, et al. 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol Psychiatry. 2002;7:805–9.

  7. 7.

    Bech P, Lonn SL, Overo KF. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. J Clin Psychiatry. 2010;71:121–9.

  8. 8.

    Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317:1358–67.

  9. 9.

    Kellner M. Drug treatment of obsessive-compulsive disorder. Dialog Clin Neurosci. 2010;12:187–97.

  10. 10.

    Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18:pyv047.

  11. 11.

    Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008;42:306–14.

  12. 12.

    Pittenger C. Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann. 2015;45:308–15.

  13. 13.

    Kang DH, Kwon JS, Kim JJ, Youn T, Park HJ, Kim MS, et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand. 2003;107:291–7.

  14. 14.

    Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, et al. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995;166:244–50.

  15. 15.

    Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology. 1999;21:683–93.

  16. 16.

    Jang JH, Kwon JS, Jang DP, Moon WJ, Lee JM, Ha TH, et al. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Am J Psychiatry. 2006;163:1202–7.

  17. 17.

    Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry. 2005;57:901–10.

  18. 18.

    Shin DJ, Jung WH, He Y, Wang J, Shim G, Byun MS, et al. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol Psychiatry. 2014;75:606–14.

  19. 19.

    Sanematsu H, Nakao T, Yoshiura T, Nabeyama M, Togao O, Tomita M, et al. Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res. 2010;44:193–200.

  20. 20.

    Yun JY, Jang JH, Kim SN, Jung WH, Kwon JS. Neural correlates of response to pharmacotherapy in obsessive-compulsive disorder: individualized cortical morphology-based structural covariance. Prog Neuropsychopharmacol Biol Psychiatry. 2015;63:126–33.

  21. 21.

    Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage. 2010;49:121–6.

  22. 22.

    Hesse S, Muller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 2005;140:63–72.

  23. 23.

    Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. J Neural Transm. 2007;114:1603–9.

  24. 24.

    Preece MA, Taylor MJ, Raley J, Blamire A, Sharp T, Sibson NR. Evidence that increased 5-HT release evokes region-specific effects on blood-oxygenation level-dependent functional magnetic resonance imaging responses in the rat brain. Neuroscience. 2009;159:751–9.

  25. 25.

    Beliveau V, Svarer C, Frokjaer VG, Knudsen GM, Greve DN, Fisher PM. Functional connectivity of the dorsal and median raphe nuclei at rest. Neuroimage. 2015;116:187–95.

  26. 26.

    Weinstein JJ, Rogers BP, Taylor WD, Boyd BD, Cowan RL, Shelton KM, et al. Effects of acute tryptophan depletion on raphe functional connectivity in depression. Psychiatry Res. 2015;234:164–71.

  27. 27.

    Ikuta T, Matsuo K, Harada K, Nakashima M, Hobara T, Higuchi N, et al. Disconnectivity between dorsal raphe nucleus and posterior cingulate cortex in later life depression. Front Aging Neurosci. 2017;9:236.

  28. 28.

    Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The yale-brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–11.

  29. 29.

    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

  30. 30.

    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.

  31. 31.

    Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, et al. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder. Mol Psychiatry. 2014;19:1025–30.

  32. 32.

    Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2:125–41.

  33. 33.

    Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142–54.

  34. 34.

    Wagner G, Krause-Utz A, De La Cruz F, Schumann A, Schmahl C, Bar KJ. Resting-state functional connectivity of neurotransmitter producing sites in female patients with borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:118–26.

  35. 35.

    Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007;37:90–101.

  36. 36.

    Edlow BL, Takahashi E, Wu O, Benner T, Dai G, Bu L, et al. Neuroanatomic connectivity of the human ascending arousal system critical to consciousness and its disorders. J Neuropathol Exp Neurol. 2012;71:531–46.

  37. 37.

    Kwon JS, Jang JH, Choi JS, Kang DH. Neuroimaging in obsessive-compulsive disorder. Expert Rev Neurother. 2009;9:255–69.

  38. 38.

    Gu BM, Park JY, Kang DH, Lee SJ, Yoo SY, Jo HJ, et al. Neural correlates of cognitive inflexibility during task-switching in obsessive-compulsive disorder. Brain. 2008;131:155–64.

  39. 39.

    Kim SG, Jung WH, Kim SN, Jang JH, Kwon JS. Disparity between dorsal and ventral networks in patients with obsessive-compulsive disorder: evidence revealed by graph theoretical analysis based on cortical thickness from MRI. Front Hum Neurosci. 2013;7:302.

  40. 40.

    Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin N Am. 2000;23:563–86.

  41. 41.

    Goodman WK, Grice DE, Lapidus KA, Coffey BJ. Obsessive-compulsive disorder. Psychiatr Clin N Am. 2014;37:257–67.

  42. 42.

    Van Der Straten AL, Denys D, Van Wingen GA. Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis. Sci Rep. 2017;7:17464.

  43. 43.

    Beucke JC, Sepulcre J, Talukdar T, Linnman C, Zschenderlein K, Endrass T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry. 2013;70:619–29.

  44. 44.

    Ahmari SE, Spellman T, Douglass NL, Kheirbek MA, Simpson HB, Deisseroth K, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340:1234–9.

  45. 45.

    Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15:410–24.

  46. 46.

    Lee J, Kim BH, Kim E, Howes OD, Cho KIK, Yoon YB, et al. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: a [(11) C]DASB PET study. Hum Psychopharmacol. 2018;33:e2642.

  47. 47.

    de Wit SJ, Alonso P, Schweren L, Mataix-Cols D, Lochner C, Menchon JM, et al. Multicenter voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am J Psychiatry. 2014;171:340–9.

  48. 48.

    Choi JS, Kim HS, Yoo SY, Ha TH, Chang JH, Kim YY, et al. Morphometric alterations of anterior superior temporal cortex in obsessive-compulsive disorder. Depress Anxiety. 2006;23:290–6.

  49. 49.

    Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. 2008;33:405–12.

  50. 50.

    Isaacs KL, Philbeck JW, Barr WB, Devinsky O, Alper K. Obsessive-compulsive symptoms in patients with temporal lobe epilepsy. Epilepsy Behav. 2004;5:569–74.

  51. 51.

    Ertekin BA, Kulaksizoglu IB, Ertekin E, Gurses C, Bebek N, Gokyigit A, et al. A comparative study of obsessive-compulsive disorder and other psychiatric comorbidities in patients with temporal lobe epilepsy and idiopathic generalized epilepsy. Epilepsy Behav. 2009;14:634–9.

  52. 52.

    Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992;72:165–229.

  53. 53.

    Brooks JC, Faull OK, Pattinson KT, Jenkinson M. Physiological noise in brainstem FMRI. Front Hum Neurosci. 2013;7:623.

  54. 54.

    Knopp J, Knowles S, Bee P, Lovell K, Bower P. A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment? Clin Psychol Rev. 2013;33:1067–81.

Download references

Author information

Correspondence to Jun Soo Kwon.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplemental material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2